Stocktoria
UroGen Pharma Ltd. URGN
UroGen Pharma Ltd. (URGN) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $109.8M at a -139.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.43 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.696 |
| Retained earnings / assets | -4.788 |
| EBIT / assets | -0.623 |
| Equity / liabilities | -0.345 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| URGN | UroGen Pharma Ltd. | 1/9 | -15.59 | — | +21.4% |
| TBPH | Theravance Biopharma, Inc. | 6/9 | 0.96 | 8.6 | +66.9% |
| ZVRA | ZEVRA THERAPEUTICS, INC. | 5/9 | -0.84 | 9 | +350.9% |
| ZYME | Zymeworks Inc. | 5/9 | -3.24 | — | +38.9% |
| GYRE | GYRE THERAPEUTICS, INC. | 3/9 | 4.52 | 71 | +10.2% |
| ASRT | Assertio Holdings, Inc. | 2/9 | -6.37 | — | -5% |
| SIGA | SIGA TECHNOLOGIES INC | 5/9 | 16.02 | 12.1 | -31.8% |
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
FAQ
Is URGN financially healthy?
UroGen Pharma Ltd.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does URGN pay a dividend?
No, UroGen Pharma Ltd. does not currently pay a dividend.
How profitable is URGN?
In FY2025, UroGen Pharma Ltd. had a net margin of -139.8%.
What is the analyst price target for URGN?
The average Wall-Street price target for UroGen Pharma Ltd. is $36.88, about 24.7% below the recent price, from 8 analysts (consensus: strong buy).
Is URGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on UroGen Pharma Ltd.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.